-
Mashup Score: 9INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases | JCO Global Oncology - 7 hour(s) ago
PURPOSEThis manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography - 1 day(s) ago
PURPOSELow-dose computed tomography (LDCT) for lung cancer screening is effective, although most eligible people are not being screened. Tools that provide personalized future cancer risk assessment could focus approaches toward those most likely to …Sybil = publicly available validated DL model 4 personalized future lung cancer risk with a single chest CT.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Regina Barzilay, the founder of Sybil, gives credit to @LeciaSequist for naming it after the prophetess in mythology believed to predict the future. #NLCRT2024 https://t.co/vAqaazw9fh https://t.co/HEQhq3FZTU
-
-
Mashup Score: 0
PURPOSEVery little is known about primary care involvement in the care of cancer survivors beyond the initial 5 years post-treatment when transitioning to primary care is guideline-recommended for many survivors.METHODSThe ICanCare study is a longitudinal …
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
Oncology and Primary Care Involvement in #BreastCancer Survivorship Care More Than 5 Years After Initial Treatment: https://t.co/qupl1x1cUO #bcsm #survonc
-
-
Mashup Score: 18Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update - 2 day(s) ago
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Systemic Therapy for Small Cell Lung Cancer: @ASCO Guideline Rapid Recommendation Update https://t.co/0K6Jf2JbMS #SCLC #lcsm
-
-
Mashup Score: 26
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Welcome to this @OncoAlert 🚨Session Round Up during #ASH24 in San Diego☀️ Todays Round up is on #MultipleMyeloma focusing on Pharmacologic Therapies: Refining the Evidence ✅GMMG-HD7 Publication: https://t.co/Rt9s0MTSuj @EliasKarlMai @RaabMarc We start off with a concomitant… https://t.co/6DNhCoxyK1 https://t.co/Pniz8iy99R
-
-
Mashup Score: 1
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 now published in @JCO_ASCO - congrats @EliasKarlMai and co-authors for tackling one of the most important unanswered #MMsm questions in our field! https://t.co/1maiXgatXJ https://t.co/cvYLczIYXu
-
-
Mashup Score: 1
Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 now published in @JCO_ASCO - congrats @EliasKarlMai and co-authors for tackling one of the most important unanswered #MMsm questions in our field! https://t.co/1maiXgatXJ https://t.co/cvYLczIYXu
-
-
Mashup Score: 0
PURPOSELymphomas are a heterogeneous group of diseases that develop in individuals of all ages and have variable prognoses. Improved survival resulting from therapy advances has led to the emergence of diverse late effects. Although several (US)–based …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Comparison of Survivorship Care Guidelines for Patients With #Lymphoma: Recommendations for Harmonization and Future Research Agenda: https://t.co/GIYnYaJ33s Authored by @BryanValcarcel et. al #lymsm #SurvOnc
-
-
Mashup Score: 17Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update - 2 day(s) ago
ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development …
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Systemic Therapy for Small Cell Lung Cancer: @ASCO Guideline Rapid Recommendation Update https://t.co/0K6Jf2JbMS #SCLC #lcsm
-
-
Mashup Score: 40
PURPOSEThe AMPLIFY trial recently established fixed-duration acalabrutinib, venetoclax, and obinutuzumab (AVO) as a new standard of care option for patients with previously untreated chronic lymphocytic leukemia (CLL) with wildtype TP53; however, due to …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Happy to share our new paper from @DanaFarber on AVO for 1L CLL with high-risk genetics just published in @JCO_ASCO https://t.co/GyqRjcpOvp
-
RT @Erman_Akkus: 📘Management of colorectal peritoneal metastases @JCOGO_ASCO 🟠Indian consensus statement 👉https://t.co/Oq1aG1qae4 @ASC…